PRACTICE Guidelines REGISTRATION PLATFORM
News MORE
  • 2023.0306

    The Development of Reporting Guideline of clinical Practice Guidelines in General Practice provides detailed guidance for the makers and writers of the general practice guidelines, which will further improve the reporting quality of the general practice guidelines, especially the Chinese general practice guidelines, and promote the application in general medical practice, thus finally improving the quality of primary medical care.

  • 2023.0220

    Professor Gordon Guyatt of McMaster University and Professor Victor Montori of the Mayo Clinic jointly published a paper in the British Medical Journal (BMJ) entitled: Guidelines should consider clinicians' time needed to treat on January 3, 2023.

  • 2022.1126

    IGEST is a generic tool for screening guidelines for any specialty, target population, and healthcare organization, but it is intended only as a screening tool, primarily for quickly assessing guideline quality and determining whether they can be adopted or adapted in other settings, and is not a substitute for some of the more complex guideline quality evaluation tools.

  • 2022.1031

    In July 2022, Jose F. Meneses-Echavez et al. from the Norwegian Institute of Public Health published an article in the Journal of Clinical Epidemiology entitled "Evidence to decision frameworks enabled structured and explicit development of healthcare recommendations". The aim of this study was to identify and describe the processes suggested for the formulation of healthcare recommendations in healthcare guidelines available in guidance documents.

Register MORE
  • 2024.0318
    The formulation of China's first "Guidelines for Exercise Prescription in Obesity" aims to further promote the development of personalized and precise exercise prescriptions.
  • 2024.0318
    Obstructive Sleep Apnea (OSA) is a common sleep breathing disorder that affects a significant portion of the Chinese population, with an estimated prevalence of 11%, impacting around 170 million individuals. Excessive daytime sleepiness (EDS) and sleep snoring with apnea are major symptoms of OSA. EDS defined as the inability to stay awake during the day, often accompanied by issues with attention and memory. Some reports approximate that 47 to 79% of patients with OSA report EDS prior to initiating therapy. Continuous Positive Airway Pressure (CPAP) therapy is the standard treatment for OSA, improving related indicators and showing a positive correlation with Epworth Sleepiness Scale scores (ESS). Despite adequate CPAP treatment, residual EDS affects 9% to 55% of patients due to multiple factors possibly involved, such as other sleep disorders, emotional and behavioral abnormalities, obesity, and medication use. Prolonging CPAP treatment duration can reduce the prevalence of residual EDS, with rates decreasing from 40% after 3 months of treatment to 13%-19% after 4 months to 2 years. While long-term CPAP therapy can extend wakefulness time, it may not fully restore daytime wakefulness. EDS impacting the patient’s family, workplace, and society, impairing work quantity and quality, increasing motor vehicle and occupational accidents, leading to mood disorders such as depression, and adding to the patient's healthcare costs. Given the potential deleterious consequences that EDS may have on patient and public safety, Europe and the United States are focusing on managing EDS in OSA patients, developing expert consensus and opinions on it. Currently, there is no comprehensive diagnostic and treatment standard for OSA induced EDS in China. Therefore, this consensus aims to provide suggestions for procedures that can be implemented into routine practice to assess for, identify, and manage EDS in patients treated for OSA.
Registration process and operational mode of a CPG registry